A fiercely competitive three-horse race in spinal muscular atrophy is Evrysdi’s for the taking.
The new price for its Covid-19 vaccine is lower than earlier deals – but arguably not by much.
By signalling that its Covid-19 vaccine could cost just a few dollars Astra could seriously embarrass its competition.
Companies and investors have not completely dismissed the UK Labour party’s proposals for cheaper drugs – but some ideas have proven more equal than others.
Novo Nordisk says that oral semaglutide’s list price will be “similar” to Ozempic’s, but it will be a while before its true cost becomes apparent.
Roche’s lower price tag for its targeted cancer therapy Rozlytrek could – intentionally or not – hit one of Bayer’s big hopes hard.
Pfizer opts not to start a price war with Alnylam and Ionis, but could there be a pricing loophole?
An Icer report questioning the cost effectiveness of Aimmune and DBV's peanut allergy projects is yet another reason to be cautious about the companies'…
An Icer white paper provides ammunition for both PBMs and pharma before the next Capitol Hill hearing.